NKTR NEKTAR THERAPEUTICS revenue, earnings and financials

For the quarter ended June 30, 2026, NEKTAR THERAPEUTICS reported revenue of $10.1M (down 9.3% from a year earlier), net income of −$40.6M and diluted EPS of −$1.23; over the last four quarters revenue was $54.6M and net income −$157M; for the fiscal year ended December 2025 revenue was $55.2M, down 43.9% on the year before.

NKTR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $55.2M, gross profit n/a, operating income −$140M, net income −$164M (margin -296.9%), EPS −$9.73
• Fiscal year ended Dec 2024: revenue $98.4M, gross profit n/a, operating income −$105M, net income −$119M (margin -120.9%), EPS −$8.68
• Fiscal year ended Dec 2023: revenue $90.1M, gross profit n/a, operating income −$264M, net income −$276M (margin -306.3%), EPS −$1.45
• Fiscal year ended Dec 2022: revenue $92.1M, gross profit n/a, operating income −$376M, net income −$368M (margin -399.8%), EPS −$1.97
• Fiscal year ended Dec 2021: revenue $102M, gross profit n/a, operating income −$446M, net income −$524M (margin -514.2%), EPS −$2.86

NKTR quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $10.1M (down 9.3% year over year), net income −$40.6M, EPS −$1.23
• Quarter ended Mar 31, 2026: revenue $10.9M (up 3.8% year over year), net income −$44.9M, EPS −$1.82
• Quarter ended Dec 31, 2025 (from the annual report): revenue $21.8M (down 25.3% year over year), net income −$36.0M, EPS −$1.29
• Quarter ended Sep 30, 2025: revenue $11.8M (down 51.1% year over year), net income −$35.5M, EPS −$1.87
• Quarter ended Jun 30, 2025: revenue $11.2M (down 52.4% year over year), net income −$41.6M, EPS −$2.95
• Quarter ended Mar 31, 2025: revenue $10.5M (down 51.7% year over year), net income −$50.9M, EPS −$3.62
• Quarter ended Dec 31, 2024 (from the annual report): revenue $29.2M (up 22.1% year over year), net income $7.22M, EPS −$2.07
• Quarter ended Sep 30, 2024: revenue $24.1M (down 0.1% year over year), net income −$37.1M, EPS −$2.66
• Quarter ended Jun 30, 2024: revenue $23.5M (up 14.6% year over year), net income −$52.4M, EPS −$3.76
• Quarter ended Mar 31, 2024: revenue $21.6M (up 0.2% year over year), net income −$36.8M, EPS −$0.19
• Quarter ended Dec 31, 2023 (from the annual report): revenue $23.9M (up 8.5% year over year), net income −$42.0M, EPS −$0.21
• Quarter ended Sep 30, 2023: revenue $24.1M (up 2.2% year over year), net income −$45.8M, EPS −$0.24
• Quarter ended Jun 30, 2023: revenue $20.5M (down 5.0% year over year), net income −$51.1M, EPS −$0.27
• Quarter ended Mar 31, 2023: revenue $21.6M (down 13.0% year over year), net income −$137M, EPS −$0.73
• Quarter ended Dec 31, 2022 (from the annual report): revenue $22.0M (down 11.9% year over year), net income −$59.5M, EPS −$0.32
• Quarter ended Sep 30, 2022: revenue $23.6M (down 5.2% year over year), net income −$59.0M, EPS −$0.31
• Quarter ended Jun 30, 2022: revenue $21.6M (down 23.8% year over year), net income −$159M, EPS −$0.85
• Quarter ended Mar 31, 2022: revenue $24.8M (up 5.0% year over year), net income −$90.4M, EPS −$0.49
• Quarter ended Dec 31, 2021: revenue $25.0M, net income −$146M, EPS −$790.00
• Quarter ended Sep 30, 2021: revenue $24.9M, net income −$130M, EPS −$0.70

NKTR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$209M, share buybacks $0
• Fiscal year ended Dec 2024: operating cash flow −$176M, share buybacks $3.00M
• Fiscal year ended Dec 2023: operating cash flow −$193M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$304M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$413M, share buybacks n/a

NKTR balance sheet

• Jun 30, 2026: cash $39.3M, total assets $1.10B, total liabilities $192M, shareholders' equity $903M
• Mar 31, 2026: cash $150M, total assets $763M, total liabilities $187M, shareholders' equity $576M
• Dec 31, 2025: cash $15.1M, total assets $280M, total liabilities $191M, shareholders' equity $89.8M
• Sep 30, 2025: cash $41.0M, total assets $301M, total liabilities $216M, shareholders' equity $85.1M
• Jun 30, 2025: cash $43.0M, total assets $208M, total liabilities $232M, shareholders' equity −$24.2M
• Mar 31, 2025: cash $38.9M, total assets $256M, total liabilities $243M, shareholders' equity $13.7M
• Dec 31, 2024: cash $44.3M, total assets $304M, total liabilities $243M, shareholders' equity $60.7M
• Sep 30, 2024: cash $30.1M, total assets $308M, total liabilities $259M, shareholders' equity $48.9M

What is NKTR's revenue?

NEKTAR THERAPEUTICS reported $54.6M of revenue over its last four quarters, through June 30, 2026.

Is NKTR profitable?

No. NEKTAR THERAPEUTICS lost $157M over the last four quarters.

What is NKTR's EPS?

Diluted earnings per share over the last four quarters were −$6.21; −$1.23 in the latest quarter.

NKTR ownership and insider trades · All stocks